
Canopy Growth Corporation’s (TSX:WEED) (NASDAQ:CGC) announced positive results from a six-month, randomized clinical trial studying the effects of cannabidiol (CBD) on menstrual-related symptoms.

Canopy Growth Corporation’s (TSX:WEED) (NASDAQ:CGC) announced positive results from a six-month, randomized clinical trial studying the effects of cannabidiol (CBD) on menstrual-related symptoms.